Mumbai, Sept. 1 -- Under this agreement, Cipla will receive exclusive rights to develop and commercialise Rolditamig Deuderuxtecan, also known as TQB2102, in India, South Africa and 5 other emerging markets.

Cipla will be responsible for local clinical development, regulatory activities, and commercialisation in the licensed territories, while CTTQ will continue to manufacture and supply TQB2102.

Chia Tai Tianqing Pharmaceutical Group Co. is a subsidiary of Sino Biopharmaceutical (SBP Group).

TQB2102 is being evaluated across HER2-expressing cancers and has demonstrated encouraging clinical potential in HER2-low advanced breast cancer.

The collaboration brings together SBP Group's differentiated late-stage oncology asset and developme...